prostate cancer

[Prostate] The authors investigated a combination therapy of novel androgen receptor (AR) antagonists and statin, simvastatin, for CRPC and found that a combination of novel AR antagonists and simvastatin could potentially affect CRPC growth through both androgen-dependent and androgen-independent mechanisms.

[Biomarkers] A new breakthrough development in cancer treatment is chimeric antigen receptor (CAR)-T cell therapy. The authors focus on its efficacy & safety in prostate cancer, obstacles impeding its clinical use, and some strategies trying to overcome them.

[Personalized Medicine] Investigators summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors.

[SOTIO Biotech] SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.

[Orion Corporation] The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor darolutamide in metastatic hormone-sensitive prostate cancer, darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival compared to placebo, docetaxel and ADT.

[Scientific Reports] Researchers characterized and investigated the effects of transient receptor potential melastatin-8 (TRPM8) modulators in prostate cancer aggressiveness disclosing the molecular mechanism underlying their biological activity.